Statin therapy is the most successful pharmacological intervention in cardiovascular medicine. In large randomized trials of high-risk populations, it reduces major cardiovascular events, heart attacks, strokes, and cardiovascular deaths, by approximately 35 percent. That result is remarkable.

It also means that 65 percent of events still occur in people whose LDL is being actively managed. On optimal therapy, with LDL driven well below clinical targets, the majority of cardiovascular events are not prevented. The question this article addresses: what is driving the rest?

The answer involves five markers that the standard lipid panel does not include: ApoB, lipoprotein(a), triglycerides, high-sensitivity C-reactive protein, and homocysteine. Each represents a distinct and independent risk channel, independent in the sense that a person can have a perfectly normal LDL and still have all five elevated simultaneously.

This is the second article in the blood tests series. The previous article covered metabolic health and insulin resistance. This one covers the lipid and inflammatory picture the standard panel misses. The cholesterol article covers the mechanism of atherosclerosis in full; this article does not repeat it, but builds on it.

Why one number is not enough

The cholesterol article on this site covers the mechanism of atherosclerosis in full: how LDL particles enter arterial walls, how they are retained and oxidized, how foam cells form, and how plaque grows. That article ends on a specific conclusion: the number that matters is not LDL cholesterol mass but the count of atherogenic particles. ApoB is that count.

The practical gap this creates is worth stating before getting into the individual markers. LDL-C measures the total mass of cholesterol carried inside LDL particles. Two people can have identical LDL-C and very different ApoB counts, different numbers of particles, because particles vary in size and cholesterol content. A person with many small, cholesterol-poor LDL particles will have a higher ApoB than a person with fewer large, cholesterol-rich particles, even if both have the same LDL-C reading.

This divergence is not an edge case. It occurs commonly in people with elevated triglycerides, metabolic syndrome, or insulin resistance: all conditions that shift LDL toward a smaller, denser particle pattern. In these people, LDL-C systematically understates their actual atherogenic particle burden. The five markers in this article capture what LDL-C misses.

ApoB: the particle count

Apolipoprotein B is the structural protein that sits on the surface of every atherogenic lipoprotein particle: LDL, VLDL, IDL, and Lp(a). Every one of these particles carries exactly one ApoB molecule, without exception. Measuring ApoB is therefore a direct count of atherogenic particles: it captures the total burden that LDL-C can only approximate.

The clinical evidence for ApoB’s superiority over LDL-C is substantial. A meta-analysis of 233,455 participants across multiple cohorts found that ApoB predicted cardiovascular events more precisely than LDL cholesterol or non-HDL cholesterol across all studied populations.^[1] The predictive advantage is largest in people where LDL-C and ApoB diverge most, specifically in people with the small dense LDL pattern produced by metabolic dysfunction and elevated triglycerides.

Small dense LDL particles matter beyond their number. They are more easily retained in arterial walls and more susceptible to oxidation than large buoyant LDL particles carrying the same cholesterol load. A shift toward small dense LDL, driven by high triglycerides and insulin resistance, raises ApoB relative to LDL-C and increases arterial risk beyond what the standard panel suggests.

Lab reference ranges for ApoB typically extend to 100 or 130 mg/dL, population-derived in the usual way. For longevity-oriented monitoring, most cardiovascular researchers consider ApoB below 80 mg/dL a reasonable general target, with below 70 mg/dL appropriate for anyone with established risk factors. The standard panel will not provide this number. It must be explicitly requested.

Lp(a): the risk you were born with

Lipoprotein(a), written Lp(a) and pronounced “L-P-little-a,” is an LDL-like particle with an additional protein called apolipoprotein(a) covalently attached. That attachment is what makes Lp(a) unusual: apolipoprotein(a) structurally resembles plasminogen, a key protein in the clot-dissolving system, and this structural mimicry gives Lp(a) pro-thrombotic properties that ordinary LDL does not have. Lp(a) drives arterial disease through both lipid deposition and impaired clot dissolution: two mechanisms for the price of one particle.

What makes Lp(a) clinically distinctive is its inheritance pattern. Approximately 90 percent of the variation in Lp(a) levels across individuals is genetically determined. Concentration is largely fixed from early adulthood and does not respond meaningfully to lifestyle changes. Diet, exercise, weight loss, and alcohol avoidance, interventions that can substantially move LDL, have little effect on Lp(a).^[2] Statin therapy, which reliably lowers LDL-C, modestly increases Lp(a) in some people. It does not lower it.

The prevalence of elevated Lp(a), defined as above 50 mg/dL or 125 nmol/L, is approximately 20 percent of the general population. At this level, Lp(a) roughly doubles the risk of coronary artery disease and myocardial infarction, independently of LDL-C and other established risk factors.^[3] The risk relationship is continuous: higher Lp(a) confers proportionally higher risk, extending well above the clinical threshold.

The practical implication follows from the biology. Because Lp(a) is genetically determined and does not respond to standard interventions, knowing your level does not immediately give you a lever to pull. What it gives you is information about your baseline risk that is otherwise invisible. For someone with elevated Lp(a), that information argues for more aggressive management of every other modifiable risk factor: lower LDL-C targets, tighter blood pressure control, no smoking. It also makes family screening relevant, since elevated Lp(a) in one person substantially raises the probability of elevated levels in first-degree relatives.

A note on units: Lp(a) is reported in either mg/dL or nmol/L, and the conversion between them is not straightforward because Lp(a) particles vary in size. A value of 50 mg/dL corresponds to approximately 125 nmol/L on average, but this relationship is approximate. Laboratories report one unit or the other; note which one is used. The clinical threshold of concern is 50 mg/dL or 125 nmol/L.

Because Lp(a) does not change, it needs to be measured only once. Order it once in adulthood, know the result, and use it as a fixed input to your long-term risk picture. Almost no standard panel includes it.

Triglycerides and the triglyceride/HDL ratio

Triglycerides are fats carried in very-low-density lipoprotein particles, VLDL. After a meal, the liver packages dietary and endogenously synthesized fat into VLDL and releases it into circulation; as VLDL delivers its triglyceride cargo to tissues, it shrinks into smaller remnant particles called IDL, which can be converted further into LDL. Triglycerides are usually included on a standard lipid panel. The problem is not that they are absent, but that the reference range fails to flag risk at the levels where damage is accumulating.

The lab considers triglycerides below 150 mg/dL to be normal. But atherogenic remnant particle burden begins increasing substantially above 100 mg/dL in the fasting state. VLDL and IDL particles are smaller and denser than standard LDL and penetrate arterial walls readily. Elevated fasting triglycerides are not merely a correlate of metabolic risk: they represent an independent lipid-particle risk channel that the standard panel catches only at high levels. A result of 130 mg/dL will not generate a flag or a conversation. From a cardiovascular standpoint, it represents a remnant particle burden meaningfully elevated relative to an optimal baseline.

The triglyceride/HDL ratio brings this into focus as a practical derived metric. It is calculated from markers already on the standard lipid panel: fasting triglycerides in mg/dL divided by HDL-C in mg/dL. A ratio above 3.0 is a strong predictor of insulin resistance and the small dense LDL particle pattern described in the ApoB section.^[4] The metabolic health article in this series discussed insulin resistance and why fasting insulin and HOMA-IR are required to measure it directly; the triglyceride/HDL ratio provides a lipid-based approximation derivable from any standard panel.

Optimal fasting triglycerides for longevity-oriented monitoring: below 100 mg/dL. Optimal triglyceride/HDL ratio: below 2.0, with below 1.5 reflecting favorable metabolic lipid health. A ratio above 3.0 warrants the full metabolic workup described in the previous article, because at that level the lipid environment is being shaped by insulin resistance rather than dietary fat alone.

hsCRP: the inflammatory channel

High-sensitivity C-reactive protein measures systemic inflammation at a resolution that standard CRP cannot reach. Standard CRP is designed to detect acute-phase responses: infections, injuries, and inflammatory flares. It is insensitive to the low-grade chronic inflammation that precedes and drives cardiovascular disease. hsCRP resolves this signal at the milligrams-per-liter level rather than tens of milligrams per liter.

The introduction to this series used the JUPITER trial to demonstrate that hsCRP adds predictive power beyond the lipid panel. The finding is worth stating precisely: JUPITER enrolled 17,802 adults with LDL below 130 mg/dL, already within the range most clinicians consider acceptable, and elevated hsCRP above 2.0 mg/L. Among these people with nominally normal cholesterol, statin therapy reduced major cardiovascular events by 44 percent.^[5] hsCRP had identified a population at elevated cardiovascular risk that the standard lipid panel would have classified as low risk.

The mechanism runs through the same atherosclerotic pathway covered in the cholesterol story: low-grade chronic inflammation accelerates the oxidation of retained lipid particles, amplifies the macrophage recruitment response, and promotes the growth of unstable plaques. Inflammation from any cause, whether metabolic dysfunction, visceral fat, sleep disruption, or periodontal disease, provides the permissive condition for atherosclerosis to advance more rapidly at any given particle burden. hsCRP does not distinguish between sources. It registers the downstream inflammatory signal regardless of where it originates.

There is a practical complication. hsCRP is sensitive to any source of inflammation: a minor infection, a dental cleaning, a minor injury, or any inflammatory episode will transiently raise hsCRP to levels that look alarming but carry no long-term cardiovascular significance. The reliable way to assess chronic inflammatory baseline is two readings at least two weeks apart, taken when entirely well, averaged. A reading above 10 mg/L almost certainly reflects acute illness rather than chronic cardiovascular inflammation and should be repeated.

Optimal hsCRP: below 1.0 mg/L. Values between 1.0 and 3.0 mg/L represent moderate cardiovascular inflammatory risk; above 3.0 mg/L represents high risk. These thresholds are from the American Heart Association’s scientific statement on hsCRP use in cardiovascular risk assessment and remain the standard clinical interpretation.

Homocysteine: vascular injury

Homocysteine is an amino acid produced as an intermediate in the metabolism of methionine, an essential amino acid found in protein-containing foods. Under normal conditions, homocysteine is rapidly recycled through two pathways, both requiring B vitamins: the remethylation pathway converts homocysteine back to methionine using folate and vitamin B12 as cofactors; the transsulfuration pathway converts it to cystathionine using vitamin B6. When any of these vitamins is insufficient, homocysteine accumulates.

Elevated homocysteine damages the endothelium, the single-cell lining of blood vessels, through several mechanisms. It generates reactive oxygen species that impair nitric oxide production, promotes platelet aggregation, and activates inflammatory pathways in vascular smooth muscle cells. The damage is independent of lipid levels: a person with entirely normal cholesterol can develop accelerated endothelial injury from chronically elevated homocysteine. A meta-analysis of 30 prospective studies found that each 5 µmol/L increase in homocysteine was associated with a 20 percent increase in coronary artery disease risk, independently of conventional lipid risk factors.^[6]

Three groups face elevated risk of accumulation. People with low B12, particularly vegetarians and vegans, are at risk because B12 is available almost exclusively from animal sources. People with MTHFR gene variants (specifically C677T, present in homozygous form in roughly 10–15 percent of people of Northern European ancestry) have impaired folate metabolism that reduces remethylation efficiency. And older adults face declining B12 absorption as gastric acid production decreases with age, making subclinical B12 depletion common even without dietary restriction.

Unlike Lp(a), elevated homocysteine is typically correctable. Supplementation with B12, B6, or methylfolate, depending on which pathway is compromised, reliably reduces homocysteine in most people. This makes it one of the few cardiovascular risk markers that is simultaneously measurable and directly modifiable. For vegetarians or anyone with MTHFR variants, periodic testing and supplementation represent a straightforward and consequential intervention.

Lab reference ranges flag homocysteine above 15 µmol/L as elevated. Risk increases continuously from approximately 10 µmol/L upward. Optimal: below 10 µmol/L. A reading of 12 to 15 µmol/L deserves attention even though it falls within the lab’s normal range.

Five markers and what optimal looks like

Each marker below covers three things: what it measures, why the lab reference range sets the bar too low, and what optimal looks like for proactive cardiovascular monitoring.

ApoB

ApoB measures the total count of atherogenic lipoprotein particles, with one ApoB molecule per particle, always. It is the most direct index of the lipid-particle burden that enters arterial walls.

Lab reference ranges typically extend to 100 or 130 mg/dL, derived from the tested population in the usual way. For longevity-oriented monitoring, optimal ApoB is below 80 mg/dL. For anyone with established cardiovascular risk factors or elevated Lp(a), below 70 mg/dL is the more appropriate target. Most labs can run it; most standard order forms do not include it.

Lp(a)

Lp(a) measures the concentration of lipoprotein(a) particles, which combine lipid deposition risk with thrombotic risk through a mechanism independent of LDL.

Lab reference ranges typically extend to 75 mg/dL or 125 nmol/L. Risk increases continuously above approximately 30 mg/dL (75 nmol/L). Optimal: below 30 mg/dL or 75 nmol/L. Order it once. The result does not change.

Triglycerides

Triglycerides measure fasting fat carried in VLDL and remnant particles. Usually included on the standard panel; the flagging threshold is set too high.

Lab considers below 150 mg/dL normal. Optimal: below 100 mg/dL fasting. Values between 100 and 150 mg/dL look unremarkable on a report but represent a metabolic state where remnant particle burden is already elevated relative to optimal.

Triglyceride/HDL ratio

Calculated from the standard panel: fasting triglycerides in mg/dL divided by HDL-C in mg/dL. Not reported by labs; must be calculated from existing results.

A ratio above 3.0 strongly predicts the small dense LDL pattern and underlying insulin resistance. Optimal: below 2.0. Below 1.5 reflects favorable lipid particle size and metabolic health.

hsCRP

hsCRP measures chronic low-grade systemic inflammation. Must be ordered as high-sensitivity CRP; standard CRP is not adequate for this purpose.

Lab high-risk threshold: above 3.0 mg/L. Moderate risk: 1.0–3.0 mg/L. Optimal: below 1.0 mg/L. Take two readings when well, at least two weeks apart, and average them. Discard any reading above 10 mg/L, which almost certainly reflects acute illness.

Homocysteine

Homocysteine measures the intermediate amino acid that accumulates when B-vitamin metabolism is impaired. Unlike the other markers here, it is typically correctable.

Lab flags above 15 µmol/L. Risk rises continuously from approximately 10 µmol/L upward. Optimal: below 10 µmol/L. Order alongside B12 to understand whether any elevation is driven by B12 deficiency specifically.

What to order

A standard lipid panel provides LDL-C, HDL-C, triglycerides, and total cholesterol. Non-HDL-C is calculated from those. That is the baseline. To it, add:

ApoB. On every lipid panel going forward. Must be explicitly requested; not included on most standard forms. Fasting is not required, though most lipid panels are drawn fasting.

Lp(a). Once in a lifetime. Order it once, know the result, and use it as a fixed input to your long-term risk picture. Note whether your lab reports in mg/dL or nmol/L: the two units are not interchangeable.

hsCRP (high-sensitivity). Must specify high-sensitivity. Standard CRP is not useful for cardiovascular risk assessment. Take two readings when well, at least two weeks apart; average them.

Homocysteine. Can be drawn fasting or non-fasting. Order alongside B12 to understand whether any elevation is driven by B12 deficiency.

Triglyceride/HDL ratio. Not a separate test. Calculate from the standard panel: fasting triglycerides (mg/dL) divided by HDL-C (mg/dL).

---

The standard lipid panel was designed to measure LDL-C because LDL-lowering therapy reduces cardiovascular events. It does. But LDL reduction accounts for roughly a third of preventable cardiovascular risk. The other five channels, particle count beyond LDL mass, a fixed genetic risk factor most people have never tested, remnant lipoprotein burden, systemic inflammation, and vascular injury from B-vitamin depletion, explain most of the rest.

The next article in this series covers hormonal balance: thyroid, testosterone, DHEA-S, and IGF-1. Read it here: Normal for Your Age.

Previous: Ten Years of Normal

References

1. Sniderman AD, Williams K, Contois JH, et al. (2011). A meta-analysis of low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337–345. https://pubmed.ncbi.nlm.nih.gov/21487090/
2. Nordestgaard BG, Chapman MJ, Ray K, et al. (2010). Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 31(23), 2844–2853. https://pubmed.ncbi.nlm.nih.gov/20965889/
3. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. (2009). Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA, 301(22), 2331–2339. https://pubmed.ncbi.nlm.nih.gov/19509380/
4. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine, 139(10), 802–809. https://pubmed.ncbi.nlm.nih.gov/14625332/
5. Ridker PM, Danielson E, Fonseca FAH, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195–2207. https://pubmed.ncbi.nlm.nih.gov/18997196/
6. Clarke R, Daly L, Robinson K, et al. (1991). Hyperhomocysteinemia: an independent risk factor for vascular disease. New England Journal of Medicine, 324(17), 1149–1155. https://pubmed.ncbi.nlm.nih.gov/2011170/